Dec 16, 2008 - MolMed appoints Professor Robert Kerbel to its Scientific Advisory Board
Nov 12, 2008 - MolMed Board of Directors approves the Interim Financial Report as of 30 September 2008
Oct 7, 2008 - MolMed partner Takara Bio Inc. starts a Phase I trial of TK for relapsed leukaemia in Japan
Sept 16, 2008 - NGR-hTNF (ARENEGYR): new and updated efficacy data of Phase II trials in three different types of solid tumours presented at ESMO 2008
Sept 15, 2008 - MolMed appoints new Director of Drug Development
Aug 29, 2008 - FDA grants Orphan Drug designation in the U.S. for the investigational antitumour drug NGR-hTNF (ARENEGYR) in the treatment of mesothelioma
Aug 27, 2008 - MolMed Board of Directors approves financial report for first half-year 2008
Jun 25, 2008 - MolMed and Avecia announce development and manufacturing agreement for ARENEGYR
Jun 6, 2008 - The European Commission grants Orphan Drug designation for MolMed vascular targeting agent ARENEGYR in the treatment of mesothelioma
May 29, 2008 - MolMed presents ARENEGYR key preliminary results of Phase II trials in mesothelioma and colorectal cancer at ASCO
May 16, 2008 - MolMed to present Phase II preliminary results for ARENEGYR at ASCO 2008
May 7, 2008 - MolMed Board of Directors approves financial report for 1Q 2008
Apr 22, 2008 - MolMed Shareholders Meeting approves Statutory Financial Statements 2007
Mar 19, 2008 - MolMed Board of Directors reviews 2007 financial statements
Jan 22, 2008 - MolMed gets approval to start Phase III of TK in high risk acute leukaemia
ARCHIVE
|
2010 |
2009 |
2008 |
2007 |
2005 |
